KR102651263B1 - Siglec15에 결합하는 항체 및 이의 용도 - Google Patents

Siglec15에 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
KR102651263B1
KR102651263B1 KR1020227030409A KR20227030409A KR102651263B1 KR 102651263 B1 KR102651263 B1 KR 102651263B1 KR 1020227030409 A KR1020227030409 A KR 1020227030409A KR 20227030409 A KR20227030409 A KR 20227030409A KR 102651263 B1 KR102651263 B1 KR 102651263B1
Authority
KR
South Korea
Prior art keywords
antibody
variable region
ser
chain variable
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227030409A
Other languages
English (en)
Korean (ko)
Other versions
KR20220158696A (ko
Inventor
밍쥬 천
슈카이 시아
Original Assignee
바이오션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오션, 인코포레이티드 filed Critical 바이오션, 인코포레이티드
Publication of KR20220158696A publication Critical patent/KR20220158696A/ko
Application granted granted Critical
Publication of KR102651263B1 publication Critical patent/KR102651263B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227030409A 2020-03-27 2021-03-26 Siglec15에 결합하는 항체 및 이의 용도 Active KR102651263B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof

Publications (2)

Publication Number Publication Date
KR20220158696A KR20220158696A (ko) 2022-12-01
KR102651263B1 true KR102651263B1 (ko) 2024-03-25

Family

ID=77891322

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227030409A Active KR102651263B1 (ko) 2020-03-27 2021-03-26 Siglec15에 결합하는 항체 및 이의 용도

Country Status (12)

Country Link
US (2) US11739147B2 (https=)
EP (1) EP4126938A4 (https=)
JP (2) JP7364315B2 (https=)
KR (1) KR102651263B1 (https=)
CN (1) CN115348970B (https=)
AU (2) AU2021240769B2 (https=)
BR (1) BR112022019129A2 (https=)
IL (1) IL296736B2 (https=)
MX (1) MX2022011951A (https=)
PH (1) PH12022552520A1 (https=)
SA (1) SA522440646B1 (https=)
WO (1) WO2021190622A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof
US20260070974A1 (en) * 2021-11-25 2026-03-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-siglec-15 antibody and use thereof
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CA3259231A1 (en) * 2022-06-13 2023-12-21 Shanghai Institute Of Biological Products Co., Ltd. ANTI-SIGLEC15 ANTIBODIES AND THEIR USES
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP2013543382A (ja) * 2010-10-05 2013-12-05 第一三共株式会社 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
ES2908046T3 (es) 2011-09-09 2022-04-27 Medimmune Ltd Anticuerpos anti-siglec-15 y usos de los mismos.
EP2832855A4 (en) * 2012-03-30 2016-02-24 Daiichi Sankyo Co Ltd NOVEL ANTI-SIGLEC-15 ANTIBODY
US9493562B2 (en) * 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2015192214A1 (en) * 2014-06-18 2015-12-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
HK1259294A1 (zh) 2015-11-10 2019-11-29 耶鲁大学 用於治疗自身免疫疾病和癌症的组合物及方法
AU2017330346C1 (en) * 2016-09-21 2025-03-06 Nextcure, Inc. Antibodies for Siglec-15 and methods of use thereof
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
JP7156653B2 (ja) * 2018-08-30 2022-10-19 イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ 固形腫瘍を治療するためのキメラ抗原受容体細胞
AU2021240769B2 (en) * 2020-03-27 2023-04-06 Biosion Inc. Antibodies binding Siglec15 and uses thereof

Also Published As

Publication number Publication date
IL296736B1 (en) 2024-12-01
CA3173201A1 (en) 2021-09-30
NZ792658A (en) 2024-07-05
US11739147B2 (en) 2023-08-29
IL296736A (en) 2022-11-01
AU2021240769B2 (en) 2023-04-06
BR112022019129A2 (pt) 2022-12-06
US20240002508A1 (en) 2024-01-04
CN115348970B (zh) 2023-11-14
WO2021190622A1 (en) 2021-09-30
AU2023203397A1 (en) 2023-06-29
US20230106715A1 (en) 2023-04-06
JP7364315B2 (ja) 2023-10-18
EP4126938A1 (en) 2023-02-08
MX2022011951A (es) 2023-03-06
CN115348970A (zh) 2022-11-15
EP4126938A4 (en) 2024-04-10
SA522440646B1 (ar) 2024-08-29
PH12022552520A1 (en) 2023-01-04
JP2023518153A (ja) 2023-04-28
IL296736B2 (en) 2025-04-01
KR20220158696A (ko) 2022-12-01
AU2021240769A1 (en) 2022-10-20
JP7827951B2 (ja) 2026-03-11
JP2024016024A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
KR102809618B1 (ko) Tslp에 결합하는 항체 및 이의 용도
KR102651263B1 (ko) Siglec15에 결합하는 항체 및 이의 용도
KR102673591B1 (ko) Pd-1에 결합하는 항체 및 그 용도
KR20220147642A (ko) Il4r에 결합하는 항체 및 이의 용도
KR20220160555A (ko) Cd40에 결합하는 항체 및 이의 용도
KR20230175298A (ko) Trop2에 결합하는 항체 및 이의 용도
KR20200143689A (ko) Pd-1 결합 항체 및 그의 용도
RU2839071C1 (ru) Антитела, связывающие siglec15, и варианты их применения
KR102934248B1 (ko) Il6r에 결합하는 항체 및 이의 용도
KR20220166795A (ko) Ctla4에 결합하는 항체 및 이의 용도
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40058295B (zh) 结合tslp的抗体及其用途
HK40058295A (en) Antibodies binding tslp and uses thereof
HK40033442B (zh) 结合pd-1的抗体及其用途
HK40033442A (en) Antibodies binding pd-1 and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220901

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231005

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240201

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240321

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240321

End annual number: 3

Start annual number: 1

PG1601 Publication of registration